Completed PHASE3 INTERVENTIONAL 2-arm NCT00122382

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate

Sponsor: Bristol-Myers Squibb

Conditions Rheumatoid Arthritis

Interventions Abatacept methotrexate placebo

Updated 7 times since 2017 Last updated: Nov 3, 2010 Started: Jul 31, 2005 Primary completion: Feb 29, 2008 Completion: Feb 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Rheumatoid Arthritis and is currently completed. Bristol-Myers Squibb leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Amsterdam, Netherlands , Antwerp, Belgium , Anyang, South Korea , Arlington, United States , Austin, United States , Berea, South Africa , Berlin, Germany , Binghamton, United States , Bloemfontein, South Africa and 68 more locations